Home / Healthcare/ FDA approves drug for loss of sexual desire in women

FDA approves drug for loss of sexual desire in women


Comments / {{hitsCtrl.values.hits}} Views / Wednesday, 3 July 2019 00:00


Reuters: The US drug regulator on Friday approved Palatin Technologies and Amag Pharmaceuticals’ drug to restore sexual desire in premenopausal women, the latest attempt to come up with a therapy that some have dubbed as “female Viagra”. 

The therapy, Vyleesi, will compete in a market which has seen previous attempts fail. Analysts have said that a drug that safely and effectively treats loss of sexual desire in women could eventually reach annual sales of about $ 1 billion. 

Palatin’s shares jumped 44% to $ 1.93, while Amag shares rose 11.5% after market. Vyleesi, chemically known as bremelanotide, activates pathways in the brain involved in sexual desire, helping premenopausal women with hypoactive sexual desire disorder (HSDD). 

The drug will compete withSproutPharmaceuticals’ Addyi, a once-daily pill that was approved for HSDD in 2015 with a warning restricting alcohol use when on the medication. It will be available from September through select pharmacies. Addyi was approved under intense pressure from advocacy groups despite a review by scientists at the Food and Drug Administration (FDA) that deemed it minimally effective and possibly unsafe. Vyleesi, which does not restrict alcohol use, is seen as having several advantages over Addyi, including tolerable side effects, rapid-acting nature and not having to take it every day, according to analysts. Side effects reported during clinical trials included mild to moderate nausea lasting no more than two hours and mostly occurred over the first three doses, Amag said. About 40% of patients in clinical trials experienced nausea. 

The drug is administered as a shot into the abdomen or thigh using an auto-injector at least 45 minutes before anticipated sexual activity, with the FDA recommending patients not to take more than one dose within 24 hours or more than eight doses per month. The drug was developed by Palatin and Amag holds exclusive North America sales rights. Palatin will get $ 60 million from Amag for the approval plus additional payments for certain sales milestones and royalties. HSDD affects about six million women in the US, but few seek or receive treatment. SVB Leerink analyst Ami Fadia said there will be a need for more direct-to-consumer advertising through social media, which could help in building awareness about HSDD. 

“These women are just suffering in silence and so the market doesn’t really exist today,” Amag CEO William Heiden said. 

Ladenburg Thalmann analyst Michael Higgins forecast Vyleesi sales could reach $ 732 million by 2030.


Share This Article

Facebook Twitter


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

An efficient energy sector for economic growth

Tuesday, 22 October 2019

When I saw the advertisement about an Energy Forum organised by PUCSL for a Policy Dialogue on the importance of an efficient energy sector for economic and investment growth, I was very happy as I have been interested in this relationship for more t


Will the rule of law, ethics, and morality be above family rule and crony rule?

Tuesday, 22 October 2019

The two main contenders for the Presidency of Sri Lanka are Gotabaya Rajapaksa and Sajith Premadasa. That is stating the obvious. No doubt, some others may have a limited impact on the outcome. Minority votes may benefit Premadasa, while the Sinhala


Botched airport opening ceremony: Sri Lanka cries

Tuesday, 22 October 2019

Last Thursday (16 October) was a great day for Sri Lanka; the Jaffna International Airport was opened. It offered a great opportunity for integrating Jaffna with the rest of Sri Lanka; for tourists from Tamil Nadu (the largest number of tourists comi


Ministry of Tourism: A nation rich in hospitality

Monday, 21 October 2019

This series is based on business leader Dhammika Perera’s recently revealed ‘Economic Growth Strategy and Action Plan to increase GDP Per Capita from $ 4,000 to $ 12,000’. The document outlines goals and action plans for 23 ministries and today


Columnists More